Fecal Microbiota Transplantation for CRE/VRE

Status Completed

Clinical Trial Summary

Multidrug-resistant organisms (MDRO) present an increasingly serious public health threat to the global community.The prevalence of various MDRO, including carbapenem-resistant Enterobacteriaceae (CRE) and vancomycin-resistant Enterococcus (VRE), has been increasing worldwide, and some have become endemic in certain countries. Data from the Hospital Authority showed that the number of carbapenemase- producing Enterobacteriaceae (CPE) cases increased from 36 in 2012 to 134 in 2015. A large outbreak of VRE involving >200 patients was recently reported in a tertiary hospital in Hong Kong. The primary site of colonization and persistence of most MDRO is in the gastrointestinal tract. Carriage can persist for months, with up to 40% of individuals still having colonization one year after hospital discharge. Outbreaks of MDRO have been reported in hospitals and long-term care facilities. Around 10% of patients colonized with MDRO would develop clinical infections by the same organism. Infections caused by these MDRO carry significant morbidity and high mortality of up to 50%, however, there is no proven therapy for eradication of intestinal colonization of MDRO. There is accumulating evidence showing that the gut microbiota plays an important role in the control of intestinal colonization and infection by pathogenic bacteria. Administration of obligate anaerobic commensal bacteria to mice has been shown to markedly reduce VRE colonization. Preliminary evidence, mainly from anecdotal reports, have shown that fecal microbiota transplantation (FMT) in human carriers of MDRO were safe and potentially effective in eliminating intestinal colonization by various MDRO, including CRE and VRE, even in immunocompromised patients. Therefore, investigators hypothesize that FMT will be safe and potentially effective in eradicating intestinal colonization of CRE and VRE. This is a prospective pilot study to evaluate whether FMT is safe and effective to eradicate intestinal colonization of CRE and VRE.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03479710
Study type	Interventional
Source	Chinese University of Hong Kong
Contact
Status	Completed
Phase	Phase 2
Start date	February 10, 2018
Completion date	July 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04182230` - UROGEN WELL D-ONE : Evaluation of a Novel Diagnostic for Sexually Transmitted Bacterial Infections
Recruiting	`NCT02814877` - Efficacy and Cost-effectiveness of Hospital Antimicrobial Stewardship Programs	N/A
Completed	`NCT03388944` - PCT Guided Stopping of Antibiotic Therapy in Children With Sepsis	N/A
Completed	`NCT05734391` - Surveillance of Healthcare-associated Infections & Antimicrobial Resistance
Completed	`NCT03794479` - Intestinal Microbiota and Antimicrobial Resistance in Hong Kong Residents After Travel
Recruiting	`NCT05942157` - Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections	N/A
Recruiting	`NCT05296837` - Ocular Rosacea Biome Study	Phase 4
Completed	`NCT05451836` - N-of-1 Trials of Interventions to Improve Decision-making for Antibiotic Use	N/A
Not yet recruiting	`NCT05960084` - Impact of Reducing Colistin Use on Colistin Resistance in Humans and Poultry in Indonesia
Completed	`NCT05445414` - A Mobile App Serious Game to Increase Awareness of Antibiotic Use in the Community	N/A
Not yet recruiting	`NCT05089760` - Microbiology, Antimicrobial Resistance and Outcomes of Neonatal Sepsis in China
Recruiting	`NCT04388293` - Using Antibiotics Wisely - An Antimicrobial Stewardship Program
Recruiting	`NCT05285657` - Algorithm Using a Rapid Diagnostic Test for the Management of Childhood Febrile Diseases.	N/A
Not yet recruiting	`NCT06358872` - Azithromycin for Child Survival in Niger II	Phase 4
Not yet recruiting	`NCT06305455` - Resistance Profile of Escherichia Coli in Infections of Community Origin: The Importance of Antimicrobial Stewardship
Not yet recruiting	`NCT06356285` - Testing New Ways to Name Antimicrobial Resistance	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.